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Feature Articles

Heart Failure: New Questions and Insights About an Old Foe

hy devote an issue of a medical joumal to aspects of heart
failure at this time? Heart failure, after all, has been recognized for centuries, and the literature is replete with articles
involving a myriad of issues relating to heart failure.
Contrary to the situation with coronary artery disease, the incidence of heart failure is increasing in this country. In 1970 an
estimated 500,000 patients were hospitalized with a diagnosis of
heart failure. Thisfiguredoubled in the next decade. Each year
an additional 400,000 individuals are diagnosed as having heart
failure, with an annual mortality rate of 10% to 20% (1).
Many reasons account for this increase. Life expectancy in
America has increased for all population groups. This is partly
related to improved living standards, but the development of
therapeutic modalities, newer and more potent antibiotics,
management of certain malignancies, and improvements in the
management of cardiovascular disease undoubtedly have contributed. Patients with hypertension, coronary artery disease,
cardiomyopathy, and valvular heart disease are managed to a
point of chronicity that was previously considered unattainable.
In this edition of the Henry Ford Hospital Medical Journal
many important issues relating to the understanding, causes,
and newer management modalities of heart failure are discussed. Advances in understanding the pathophysiology of heart
failure are summarized (2). These advances have spurred the
whole spectrum of clinical and bench cardiological research
which is cunently conducted at a biochemical and subcellular
level. The possible role of platelets in the thromboembolic complications of patients with heart failure is also discussed (3).
As our ability to treat heart failure improves, signs of congestion are seen less frequently, even in patients with severe pump
dysfunction. Problems associated with this change in the manifestation of myocardial dysfunction are reported by Jafri et al
(4). Echocardiography is extremely useful and in many instances complements the clinical evaluation of patients with
heart failure. Alam (5) discusses the role of this noninvasive
procedure along with the important differential features of the
various causes of heart failure.
Garcia and Alam (6) highlight the restrictive cardiomyopathies, particularly amyloid heart disease which is more frequently diagnosed premortem because of the routine availability
of echocardiography. The protean manifestations of this condition are also noted. A high index of suspicion is necessary to
make the diagnosis, and echocardiography should be considered whenever the presentation of heart failure is somewhat
atypical, especially in elderly patients.
Sudden death is an important cause of demise in this patient
population. The majority of patients with heart failure still re-
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ceive digoxin and diuretic therapy. Rosman et al (7) discuss the
possibility of electrolyte imbalance, particularly potassium abnormalities, as a contributing factor to sudden death in these
individuals.
In the realm of patient management, classic therapeutic interventions such as digitalis still play an important role. With better
understanding of the effects of acute and chronic digitalis therapy, a more rational approach for its use is possible (8). Goldstein (9) reviews the apparent paradox of using beta-blockade in
selected patients with heart failure and the theory behind such
use. A host of inotropic agents have been recently introduced
into the therapeutic armamentarium for the management of
heart failure. Their mechanism of action, benefits, and disadvantages are presented by Jafri and Bristol (10).
Controversy exists regarding the timing of surgery in the
management of patients with valvular disease. Early surgery has
been recommended to prevent ineversible left ventricular dysfunction. Lee et al (11) report the results following aortic valve
replacement in patients with aortic stenosis or regurgitation. Improvement in ventricular function generally can be expected, although in certain instances improvement may be delayed.
Finally, stemming from advances in renal transplantation and
the improved ability to control rejection, cardiac transplantation
has advanced from an experimental procedure to that of an
important therapeutic option in patients with end-stage heart
failure (12),
This edirion of the Journal is not intended to be a comprehensive review of all the advances or changes in the pathophysiology, diagnosis, or management of patients with heart
failure. Neither is it our intent to supply all the answers. However, we pinpoint several areas of this vast subject where advances have changed prior dogma and also attempt to place some
of the issues in perspective. Each new insight or advance often
produces further complications and poses more problems. At
best we can hope to improve patients' quality of life and perhaps
extend their survival by better understanding the disease process
and its management.
Jeffrey B. Lakier, MD
Staff Physician, Henry Ford Hospital
Heart and Vascular Institute
Division of Cardiovascular Medicine
Guest Editor
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